Accessibility Menu
GeoVax Labs logo

GeoVax Labs

(NASDAQ) GOVX

Current Price$0.96
Market Cap$5.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-100%
5 Year-100%
1 Year-95%
1 Month-17%
GeoVax Labs last closing stock price
MetricPriceDate
Last closeUSD 0.972026-07-17
GeoVax Labs stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-17.44%USD 1.182026-07-10
1 month-17.44%USD 1.182026-06-17
3 month-21.44%USD 1.242026-04-17
Year to date-77.21%USD 4.282025-12-31
1 year-94.67%USD 18.272025-07-17
3 year-99.55%USD 217.502023-07-18
5 year-99.94%USD 1,567.502021-07-16
Since inception-100%USD 6,800,000,000.002006-09-29

GeoVax Labs Financials at a Glance

Market Cap

$5.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$852.28K

Net Income (TTM)

-$21.37M

EPS (TTM)

-$21.70

P/E Ratio

-0.04

Dividend

$0.00

Beta (Volatility)

1.36 (Average)

Price

$0.96

Volume

5,024

Open

$1.00

Previous Close

$0.96

Daily Range

$0.95 - $1.00

52-Week Range

$0.82 - $23.10

Estimated Earnings Date

Jul 27, 2026

GOVX News

Foolcom-Featured.png

GeoVax Labs Revenue Doubles in Q2

Motley Fool Markets TeamJul 29, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GeoVax Labs

GeoVax develops vaccines and therapies for infectious diseases and cancer. Its products aim to help people with weak immune systems or rare cancers. The company’s work supports public health and medical research needs.

Shots, Genes, and More: What GeoVax Sells

  • COVID-19 Vaccine (GEO-CM04S1): Next-generation vaccine in Phase 2 trials, focused on people with weak immune systems. (The company’s revenue to date has come from government grants, contracts, and collaborative arrangements in support of product development.)
  • Mpox/Smallpox Vaccine (GEO-MVA): Vaccine candidate for Mpox and smallpox, moving toward late-stage trials.
  • Gene Therapy for Cancer (Gedeptin): Therapy for head and neck cancer, completed early trials, with more planned.
  • Other Vaccines: Early-stage vaccines for HIV, Zika, malaria, and hemorrhagic fevers like Ebola.
  • Manufacturing Platform: Uses a bird cell-based system for efficient vaccine production, replacing traditional egg-based methods.

GeoVax on the Move: Growth and Expansion

  • Partnered with National Institutes of Health, CDC, and U.S. Department of Defense for research support (ongoing).
  • Advanced COVID-19 vaccine to multiple Phase 2 trials in 2024-2025.
  • Completed early trial for Gedeptin cancer therapy in 2024; Phase 2 planned.
  • Received guidance from the European Medicines Agency to move Mpox/smallpox vaccine directly to Phase 3 in 2025.
  • Raised $5.6 million in July 2025 through a public stock offering.

GeoVax: The Secret Sauce

GeoVax’s proprietary vaccine platform uses a modified virus to trigger immune responses. Its focus on hard-to-treat diseases and scalable manufacturing sets it apart. Strategic partnerships help validate and advance its pipeline.

Five Things You Need to Know

  • Revenue was $852,282 in Q2 2025, up 183.5% from Q2 2024.
  • All revenue comes from U.S. government contracts; no product sales yet.
  • Net loss was $5.37 million in Q2 2025, Net loss worsened by 6% year-over-year.
  • Cash and equivalents were $3.09 million as of June 30, 2025.
  • GeoVax raised approximately $5.6 million in July 2025.

Bottom Line

GeoVax is a small biotech focused on vaccines and cancer therapies. Its future depends on continued funding and successful clinical progress.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

19

CEO

David A. Dodd

Website

www.geovax.com

Headquarters

Smyrna, GA 30080, US

GOVX Financials

Key Financial Metrics (TTM)

Gross Margin

-1500.67%

Operating Margin

-2523.43%

Net Income Margin

-2507.27%

Return on Equity

-709.51%

Return on Capital

-463.53%

Return on Assets

-716.50%

Earnings Yield

-25.00%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

5.21M

Volume

5.02K

Avg. Volume

5.17M

Financials (TTM)

Gross Profit

-$12.79M

Operating Income

-$21.51M

EBITDA

-$21.48M

Operating Cash Flow

-$19.05M

Capital Expenditure

-$10.73K

Free Cash Flow

-$19.06M

Cash & ST Invst.

$1.27M

Total Debt

$394.57K

GeoVax Labs Performance Analysis

GeoVax Labs annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 3,954,576N/A
20252025-12-31USD 2,489,145-37.1%
GeoVax Labs sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-47.9%
Q32025-09-30-100.0%
Q42025-12-31N/A
Q12026-03-31N/A
GeoVax Labs annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -309.78-72.9%
20232023-12-31USD -357.2215.3%
20242024-12-31USD -120.46-66.3%
20252025-12-31USD -22.40-81.4%
GeoVax Labs sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3022.2%
Q32025-09-3011.4%
Q42025-12-3167.1%
Q12026-03-31-2.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$3.90M

-5.0%

Gross Margin

0.00%

N/A

Market Cap

$5.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$267.16K

N/A

Employees

19

N/A

Net Income

-$5.26M

+1.8%

EBITDA

-$5.25M

+1.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$1.27M

-82.9%

Total Debt

$394.57K

N/A

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$197.10K

N/A

Short Term Debt

$197.47K

N/A

Return on Assets

-7.16%

N/A

Return on Invested Capital

-31.13%

N/A

Free Cash Flow

-$3.54M

+40.9%

Operating Cash Flow

-$3.54M

+40.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
AIMDAinos, Inc.
$1.59-3.64%
ICUSeaStar Medical Holding Corporation
$3.85-3.75%
MBRXMoleculin Biotech, Inc.
$2.14+1.90%
LNAILunai Bioworks Inc.
$2.64-6.38%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$6.87+0.05%
PATHUiPath
$12.16+0.00%
ZYBTZhengye Biotechnology
$8.01+10.48%
AALAmerican Airlines Group
$15.14+0.01%

Questions About GOVX

What is the current price of GeoVax Labs?

GeoVax Labs is trading at $0.96 per share.

What is the 52-week range for GeoVax Labs?

Over the past 52 weeks, GeoVax Labs has traded between $0.82 and $23.10.

How much debt does GeoVax Labs have?

As of the most recent reporting period, GeoVax Labs reported total debt of $394.57K.

How much cash does GeoVax Labs have on hand?

GeoVax Labs reported $1.27M in cash and cash equivalents in its most recent financial results.

What is GeoVax Labs’s dividend yield?

GeoVax Labs does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services